Why do ADCs against the same target succeed or fail?
Several ADCs chase the same receptor and only one gets approved, what actually separates the winner, and where should a next-gen molecule compete?
Antibody-drug conjugates are oncology's fastest-growing class, but most against a given target fail on a narrow therapeutic window. We used Hydra to benchmark four FRα ADCs on public data: the approved agent's lead comes almost entirely from patient selection, a replicable choice, while payload permeability is the biggest untapped engineering lever.
Who this is for: ADC engineers, antibody and medicinal-chemistry teams evaluating or designing a next-generation antibody-drug conjugate.
- clinical trials mined for the landscape
- 39
- binding-affinity floor a best-in-class must match
- 1.8 nM
- max correlation of expression with ADC processing
- r = 0.20
- leader's composite (0.731 from patient selection)
- 0.739
clinical trials mined for the landscape
binding-affinity floor a best-in-class must match
max correlation of expression with ADC processing
leader's composite (0.731 from patient selection)
The problem ADC teams keep running into
Antibody-drug conjugates are the fastest-growing class in oncology, but the failure rate is unforgiving: multiple ADCs are often developed against the same receptor and only one reaches approval. The therapeutic window is narrow, and teams argue endlessly over which lever decides it, binding affinity, payload, linker stability, drug-to-antibody ratio, or patient selection.
The honest answer is usually buried. Tumour target expression is heterogeneous, so even a well-chosen patient has antigen-low cells; a payload that can't diffuse into neighbours (the bystander effect) leaves them alive, while too high a DAR stacks toxicity. Reconciling all of that means pulling binding data, antibody structure, payload chemistry, and tumour transcriptomics from four different places, slow, manual work most teams never finish.
What teams in this space search for
- Why do ADCs against the same target succeed or fail?
- How do I widen my ADC's therapeutic window?
- Does my ADC payload need to be bystander-capable?
How we solved it with Hydra
“Benchmark every clinical-stage ADC targeting folate receptor alpha (FRα) in ovarian cancer. Pull the competitive landscape, antibody binding and epitope geometry, payload physicochemistry, and tumour expression, then score each agent on affinity, epitope distance, payload permeability, and patient-selection stringency. Tell me what a best-in-class molecule would have to beat, and which dimensions are intrinsic to the molecule versus replicable programme design.”
What Hydra ran
Hydra integrated four public sources: clinical-trial records (ClinicalTrials.gov, 39 trials), the FRα crystal structure (PDB 4LRH, 2.80 Å), payload physicochemistry (PubChem), and ovarian-tumour expression (TCGA / cBioPortal, ~300 samples).
It scored every agent on four dimensions in two categories, intrinsic ADC properties (binding affinity, epitope distance from the folate pocket, payload permeability) and programme design (clinical-stratification stringency), and separately correlated FOLR1 expression against five markers of the intracellular processing pathway to test whether "high-expressing" actually means "efficiently killed."
What it found
The approved agent scored highest overall (composite 0.739), but 0.731 of that came from its patient-selection programme: ~73% of its trials require explicit FRα thresholds (often ≥75% by IHC), versus 25–33% for competitors. On intrinsic molecule properties the field is far more even.
Binding affinity: the leader's ~1.8 nM sets the competitive floor; the weakest competitor at 6.5 nM is 3.6× weaker. Payloads span all three permeability classes (high to low). And FOLR1 expression correlated only weakly with processing markers, the strongest at r=0.20 (~4% of variance), the rest near zero.
What we learned
Patient selection (≥75% IHC) is now table stakes, not a moat, any competitor can adopt the same threshold retrospectively. The durable advantage is intrinsic: affinity, epitope, and especially payload permeability.
Because expression doesn't predict efficient processing, even a perfectly enriched patient has cells that bind but don't kill, so a high-permeability payload, which reaches them via the bystander effect, is the single biggest lever. The resulting best-in-class spec: affinity ≤2 nM, a high-permeability payload, ≥75% IHC selection, and possibly a novel epitope for differentiation.
What you get
- A best-in-class design spec: ≤2 nM affinity, high-permeability payload, ≥75% IHC selection, possible novel epitope
- A clean split between replicable programme design and intrinsic molecular advantage
- Transcriptomic evidence that expression ≠ efficient processing, the quantitative case for permeable payloads
- Weeks of manual landscape research compressed into a reviewable, fully-sourced first draft
Data sources used
- ClinicalTrials.gov (39 trials, FRα eligibility criteria)
- RCSB PDB 4LRH (folate-pocket & epitope geometry)
- PubChem (payload XLogP, TPSA, MW)
- cBioPortal / TCGA (~300 ovarian tumours)
Figures reflect analyses PharosBio ran on public datasets and public benchmarks. Named competitors, collaborators, and logos are withheld at this stage; the methods and results shown are real and repointable to your own target.
Sources & methods
- FRα structure: RCSB PDB 4LRH (Chen et al., PNAS 2013)
- Permeability thresholds: Veber et al., J Med Chem 2002; Kovtun et al., Cancer Res 2006
- Bystander killing: Kovtun et al. 2006; Li et al., Cancer Res 2016
- Landscape & expression: ClinicalTrials.gov; PubChem; cBioPortal / TCGA
Frequently asked questions
Is a tighter binding affinity always better for an ADC?
No. The ~1.8 nM benchmark sets a competitive floor and 6.5 nM (3.6× weaker) is likely too weak, but very high affinity can trap antibodies in peripheral tumour layers (the binding-site barrier) and reduce penetration. Aim for ≤2 nM and balance occupancy against penetration.
Why does payload permeability matter more than patient selection?
Patient selection (≥75% FRα by IHC) is replicable, and IHC measures surface protein at one time point, not whether the cell processes the ADC. A high-permeability payload extends killing to antigen-low and poorly-processing neighbours via the bystander effect, an intrinsic advantage selection can't replicate.
Can this benchmark be repointed at another target?
Yes. The workflow, trials, structure, payload chemistry, transcriptomics, integrated scoring, runs on public data, so Hydra can repoint it at any target, indication, or competitive set in hours rather than a quarter.
Run this analysis on your question
Hydra plans, executes, and validates, so you reach a defensible answer in hours, not weeks.